Heart Failure

Heart failure occurs when the heart cannot pump as much blood as the body requires. This ineffective pumping can lead to enlargement of the heart as the myocardium works harder pump the same amount of blood. Heart failure may be caused by defects in the myocardium, such as an a heart attack infarct, or due to structural issues such as severe heart valve regurgitation. Heart failure can be divided into HF with preserved ejection fraction (HFpEF), and HF with reduced ejection fraction (HFrEF). The disease is further divided into four New York Heart Association (NYHA) classes. Stage IV heart failure is when the heart is completely failing and requires a heart transplant or hemodynamic support from a left ventricular assist device (LVAD).

RSS icon

Abiomed Announces First Patient Treated with Impella® in Japan

DANVERS, Mass., Oct. 26, 2017 — Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, announced today the first patient treated with the Impella heart pump in Japan. The Impella 2.5® and Impella 5.0® heart pumps are approved for the treatment of drug-resistant acute heart failure and are the first and only percutaneous temporary ventricular support devices Pharmaceuticals and Medical Devices Agency (PMDA) approved in Japan.

Children awaiting heart transplant survive longer with VADs than ECMO

Ventricular assist devices (VADs) foster improved survival for children awaiting heart transplantation when compared to the current standard of extracorporeal membrane oxygenation (ECMO), according to a new study in the Journal of the American College of Cardiology.

Thumbnail

AHA: Blacks living shorter lives due to CVD, stroke

African Americans are dying an average of 3.4 years before white Americans, a significant gap that’s attributable to more prevalent cardiovascular disease (CVD) and risk factors in the black population, the American Heart Association (AHA) reported in a scientific statement published Monday in Circulation.

Thumbnail

Researchers call for more patient-centered designs, outcomes in cardiovascular trials

Cardiovascular research has traditionally focused on hard clinical endpoints such as markers of disease progression, adverse events and death. But now researchers are calling for more studies that incorporate the viewpoints of patients and caregivers, both in trial design and execution and in measuring outcomes like quality of life, time off work, out-of-pocket expense and caregiver burden.

Aerobic workouts, combined with yoga, drastically reduce CVD risk factors

Combining Indian yoga and aerobic exercise can dramatically reduce blood pressure, body mass index and cholesterol levels in cardiac patients, the American College of Cardiology has reported.

Thumbnail

Digital trackers help cardiac rehab patients boost activity on their own time

Digital tracking devices can motivate patients to increase their physical activity outside of structured cardiac rehabilitation, a new study suggests.

Cardiologists set to present new data at China congress

Chinese cardiologists will be presenting their latest data on cardiovascular disease at the 28th Great Wall International Congress of Cardiology this weekend.

Thumbnail

Black women face double the risk of pregnancy-related heart failure

Peripartum cardiomyopathy (PPCM) strikes black women harder than other races, both in frequency and the ability to recover, according to a report published in JAMA Cardiology.

Displaying 713 - 720 of 1270

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.